Timber Pharmaceuticals Inc. (AMEX: TMBR) is 169.18% higher on its value in year-to-date trading and has touched a low of $0.67 and a high of $10.44 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The TMBR stock was last observed hovering at around $2.25 in the last trading session, with the day’s loss setting it -0.25% off its average median price target of $12.00 for the next 12 months. It is also 83.33% off the consensus price target high of $12.00 offered by 1 analysts, but current levels are 83.33% higher than the price target low of $12.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Currently trading at $2.00, the stock is -9.01% and 2.21% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.25 million and changing -11.11% at the moment leaves the stock 34.89% off its SMA200. TMBR registered -36.51% loss for a year compared to 6-month gain of 102.51%. The firm has a 50-day simple moving average (SMA 50) of $2.1473 and a 200-day simple moving average (SMA200) of $1.3311.
The stock witnessed a 9.29% loss in the last 1 month and extending the period to 3 months gives it a 137.59%, and is -3.85% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 11.97% over the week and 17.19% over the month.
Timber Pharmaceuticals Inc. (TMBR) has around 6 employees, a market worth around $66.48M and $0.50M in sales. Distance from 52-week low is 200.71% and -80.84% from its 52-week high. The company has generated returns on investments over the last 12 months (-266.40%).
Timber Pharmaceuticals Inc. (TMBR) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Timber Pharmaceuticals Inc. (TMBR) is a “Hold”. 1 analysts offering their recommendations for the stock have an average rating of 3.00, where 1 rate it as a Hold and 0 think it is a “Overweight”. 0 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Timber Pharmaceuticals Inc. quarterly earnings per share for the current quarter are estimated at $0.The EPS is expected to grow by 89.20% this year.
Timber Pharmaceuticals Inc. (TMBR) Top Institutional Holders
12 institutions hold shares in Timber Pharmaceuticals Inc. (TMBR), with 5.62M shares held by insiders accounting for 15.26% while institutional investors hold 3.99% of the company’s shares. The shares outstanding are 26.32M, and float is at 6.41M with Short Float at 58.90%. Institutions hold 3.38% of the Float.
The top institutional shareholder in the company is Bridgeway Capital Management, Inc. with over 0.16 million shares valued at $0.12 million. The investor’s holdings represent 0.43% of the TMBR Shares outstanding. As of Dec 30, 2020, the second largest holder is Two Sigma Securities, LLC with 17578.0 shares valued at $13060.0 to account for 0.05% of the shares outstanding. The other top investors are UBS Group AG which holds 12978.0 shares representing 0.04% and valued at over $9642.0, while Advisory Services Network, LLC holds 0.01% of the shares totaling 3005.0 with a market value of $2232.0.
Timber Pharmaceuticals Inc. (TMBR) Insider Activity
The most recent transaction is an insider sale by TardiMed Sciences LLC ,the company’s10% Owner. SEC filings show that TardiMed Sciences LLC sold 100,694 shares of the company’s common stock on Sep 16 at a price of $1.03 per share for a total of $0.1 million. Following the sale, the insider now owns 5.44 million shares.
Timber Pharmaceuticals Inc. disclosed in a document filed with the SEC on Sep 15 that TardiMed Sciences LLC (10% Owner) sold a total of 87,060 shares of the company’s common stock. The trade occurred on Sep 15 and was made at $1.03 per share for $89550.0. Following the transaction, the insider now directly holds 5.54 million shares of the TMBR stock.
Still, SEC filings show that on Sep 14, TardiMed Sciences LLC (10% Owner) disposed off 455 shares at an average price of $1.03 for $469.0. The insider now directly holds 5,625,271 shares of Timber Pharmaceuticals Inc. (TMBR).